Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children

B J Lipworth, D J Clark, L C McFarlane

Abstract

Background – In a previous single dosing study in asthmatic school children fluticasone propionate produced significantly greater suppression of overnight urinary cortisol excretion than budesonide at high doses of 800 µg/day or greater. The aim of this study was to assess whether conventional lower doses of both drugs cause adrenal suppression when given at steady state twice daily by large volume spacer on a microgram equivalent basis in asthmatic school children.

Methods – Eight school children of mean age 12.1 years with stable asthma of mild to moderate severity (forced expiratory volume in one second (FEV₁) 78.6% predicted, mid forced expiratory flow rate (FEF₂₅₋₇₅) 72.5% predicted), on 400 µg/day or less of inhaled corticosteroid, were studied in a single blind (investigator blind), placebo controlled, crossover design comparing inhaled budesonide and fluticasone propionate 100 µg bid and 200 µg bid. Each dose was given at 08.00 hours and 20.00 hours for four days by metered dose inhaler via their respective large volume spacers with mouth rinsing. Measurements were made of overnight urinary cortisol and creatinine excretion after the eighth dose.

Results – Neither drug produced significant suppression of overnight urinary cortisol or cortisol/creatinine excretion compared with pooled placebo and there were no differences between the drugs. Only one subject with each drug at 200 µg twice daily had abnormally low urinary cortisol excretion of <10 nmol/12 hours. Ratios for the fold difference between active treatment versus placebo for urinary cortisol excretion were (as means and 95% confidence intervals for difference): budesonide 100 µg bid 1.03 (95% CI 0.46 to 1.61), budesonide 200 µg bid 1.04 (95% CI 0.62 to 1.46); fluticasone 100 µg bid 1.11 (0.45 to 1.77), fluticasone 200 µg bid 1.12 (0.78 to 1.47). Likewise, there were no significant differences in overnight urinary cortisol/creatinine excretion.

Conclusions – With repeated twice daily administration at steady state across a dose range of 200–400 µg/day no evidence of significant adrenal suppression was found using the sensitive marker of overnight urinary cortisol excretion for either flu-

ticasonone propionate or budesonide given via a large volume spacer. These results emphasise the good safety profile in children of these inhaled steroids at conventional dose levels, which have proven antiasthmatic efficacy.

(Thorax 1997;52:686-689)

Keywords: adrenal activity, chronic dosing, inhaled corticosteroids, asthmatic children, fluticasone propionate, budesonide.

Inhaled corticosteroids have a well established role as first line preventive anti-inflammatory treatment in the treatment of childhood asthma.^{1,2} However, increased use of inhaled corticosteroids has focused greater attention on their systemic side effect profiles. Of these systemic effects, adrenal suppression is one of the most sensitive accessible markers currently available.

In a previous study in asthmatic children of similar severity we have found significant differences between inhaled fluticasone propionate and budesonide for the degree of adrenal suppression induced when they were given on a microgram equivalent basis.³ This was seen with single evening doses of 800 µg or greater, with fluticasone causing significant adrenal suppression whereas budesonide caused none. These differences between single doses of fluticasone and budesonide can be explained by the pharmacological properties of fluticasone which has both greater glucocorticoid receptor potency and receptor residency time than budesonide.^{4,5}

However, of greater clinical relevance is the degree of adrenal suppression seen at steady state with repeated twice daily dosing as this more accurately reflects what may be expected in everyday clinical practice. Although high doses of inhaled fluticasone propionate outwith the conventional dose range are known to cause clinically relevant growth and adrenal adverse effects,⁶ most asthmatic children will be maintained on doses of no more than 400 µg/day. The aim of this study was therefore to investigate steady state suppressive effects with inhaled fluticasone propionate and budesonide on adrenal activity across a clinically relevant dose range of 100–200 µg twice daily in asthmatic children.

Methods

PATIENTS

Eight asthmatic children (outpatients) of mean (SE) age 12.1 (0.5) years completed the study.

Department of Clinical Pharmacology and Respiratory Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK
B J Lipworth
D J Clark
L C McFarlane

Correspondence to:
Dr B J Lipworth.

Received 19 December 1996
Returned to authors
17 February 1997
Revised version received
24 April 1997
Accepted for publication
25 April 1997

All cases were considered to have stable asthma of mild to moderate severity. Their mean forced expiratory volume in one second (FEV_1) was 1.99 (0.14) l, 78.6 (4.7)% of predicted, and mid forced expiratory flow rate (FEF_{25-75}) was 2.18 (0.24) l/s, 72.5 (7.5)% of predicted. Both parents and children gave written informed consent. Approval for the study was given by the Tayside medical ethics committee for measurement of overnight urinary cortisol excretion but not plasma cortisol levels. All the children were continent of urine day and night. The subjects were taking 400 µg/day or less of inhaled corticosteroid (median dose 400 µg/day), beclomethasone dipropionate (Becodisk) 400 µg/day (six patients) and fluticasone propionate (Diskhaler) 200 µg/day (two patients). None had received oral corticosteroids within the preceding six months.

PROTOCOL

A single blind (investigator blind), placebo controlled, randomised crossover design was used with twice daily dosing over four days at each dose level. The duration of each treatment was chosen to ensure steady state drug levels. Subjects attended an initial screening visit where FEV_1 and FEF_{25-75} were measured using a Vitalograph Compact spirometer (Vitalograph Ltd, Buckingham, UK), having withheld inhaled bronchodilators for eight hours. Detailed instruction in correct usage of metered dose inhaler (MDI) and spacer combinations were given according to the manufacturers' recommendations.

Subjects were then randomised to receive treatment for eight days in crossover fashion with either fluticasone propionate (Flixotide MDI, 50 µg per actuation, Allen and Hanburys, Uxbridge, Middlesex, UK), 100 µg and 200 µg twice daily or budesonide (Pulmicort MDI, 50 µg per actuation, Astra Pharmaceuticals, Kings Langley, Herts, UK) 100 µg and 200 µg twice daily, each dose being given sequentially for four days. These were given in conjunction with their respective large volume spacer (Nebuhaler or Volumatic) according to manufacturers' instructions, using single puffs with no delay. Correct use of the spacer was checked prior to inclusion into the study as well as at each study visit. Randomisation was in balanced blocks with four given fluticasone first and four receiving budesonide first. Placebo MDI (plus spacer) was given for four days prior to the start of each of the two eight day treatment periods. There was at least a 12 day washout period between the two 12 day sequences during which the patients resumed their standard inhaled steroid therapy.

The aerosol canisters and plastic actuators were masked and placed in identical boxes. Each treatment box was dispensed by a different person from the investigator in order to keep the investigator blinded. Subjects omitted their usual steroid inhaler for the duration of each 12 day sequence. Mouth rinsing was performed after each two puffs of their study inhaler. After seven doses at each dose level, immediately before taking the eighth dose at

20.00 hours, subjects emptied their bladder and collected all their overnight urine for 12 hours until 08.00 hours the following morning. No further steroid or bronchodilator inhalers were taken until completion of the urine collection.

MEASUREMENTS

Overnight 12 hour urinary free cortisol excretion and creatinine excretion were measured. The urinary cortisol was measured using a commercial radioimmunoassay kit (Incstar, Wokingham, Berkshire, UK) with an intra-assay and interassay coefficient of variability for analytical imprecision of 9.94% and 9.50%, respectively. Urinary creatinine was measured on a Cobas-Bio autoanalyser (Roche Products Ltd, Welwyn Garden City, Herts, UK) and the intra-assay and interassay coefficients of variability for analytical imprecision were 4.55% and 0.63%, respectively. We have previously reported an intrasubject coefficient of variation of 5.4% for measurement of overnight urinary cortisol excretion in asthmatic children.³

STATISTICAL ANALYSIS

The power of the study was 80% in order to detect a 30% difference from placebo in overnight urinary cortisol excretion on the basis of a previous study with budesonide and fluticasone propionate in asthmatic children.³ All data were analysed using a Statgraphics software package (STSC Software Group, Rockville, Maryland, USA). The data were initially subjected to a plot to assess whether they conformed to a normal distribution and were then analysed by comparing the pooled placebo with both drugs at both dose levels using a multifactorial analysis of variance (MANOVA) with treatments, doses, subjects, and periods as factors. This was followed by Bonferroni multiple range testing in order to obviate multiple pairwise comparisons. The urinary cortisol/creatinine ratio data were analysed as trimmed means to account for three outlying data points above a ratio of 20 (these are depicted in fig 2, one for budesonide 100 µg bid, one for fluticasone 100 µg bid, and one for fluticasone 200 µg bid). The cortisol/creatinine data conform to a normal distribution when analysed in this way. A probability value of <0.05 (two-tailed) was accepted as being significant. Ratios were calculated for the differences between each active treatment and placebo and expressed as a fold difference with 95% confidence interval (for intra-individual differences).

Results

There were no significant differences between the first and second placebos given in sequence for either overnight urinary cortisol excretion (that is, placebo 1 versus placebo 2): 22.5 nmol/12 h versus 23.5 nmol/12 h or for overnight urinary cortisol/creatinine excretion: 6.84 nmol/mmol versus 6.28 nmol/mmol. There were also no significant differences between placebo values prior to each treatment

Figure 1 Individual values for overnight urinary free cortisol excretion at each dose level for repeated steady state dosing with budesonide (BUD) and fluticasone propionate (FP) or pooled placebo. No significant differences were found between the treatments or versus placebo. Values are shown as means and 95% CI.

Figure 2 Individual values for overnight urinary cortisol/creatinine ratio at each dose level for repeated steady state dosing with budesonide (BUD) and fluticasone propionate (FP) or pooled placebo. No significant differences were found between the treatments or versus placebo. Values are shown as trimmed means and 95% CI. There were three outlying data points with a ratio of >20 which were removed when calculating the trimmed means.

for either urinary cortisol excretion (that is, placebo prior to budesonide versus placebo prior to fluticasone): 20.9 nmol/12 h versus 24.6 nmol/12 h or for urinary cortisol/creatinine excretion: 6.53 nmol/mmol versus 6.63 nmol/mmol.

The results for overnight urinary cortisol and cortisol/creatinine excretion did not reveal any significant suppression with either drug

compared with placebo. There were also no significant differences between the two drugs. These data are depicted in figs 1 and 2 as means and individual values to show dispersion. The ratios for suppression with active drug versus placebo are shown in table 1 as means and 95% CI for within subject differences. There were two low urinary cortisol results (<10 nmol/12 h), one each for fluticasone 200 µg bid and budesonide 200 µg bid.

Discussion

The results of this study show that inhaled budesonide and fluticasone propionate at doses up to 200 µg twice daily via large volume spacer do not cause any detectable adrenal suppression at steady state using the sensitive marker of overnight urinary cortisol excretion. As a consequence of the relatively small sample size it is conceivable that we may have missed a change in overnight urinary cortisol excretion amounting to 30% or less. Nonetheless, in terms of clinical relevance only one patient with each drug at 200 µg twice daily had an abnormally low overnight urinary cortisol excretion (<10 nmol/12 h). These findings should offer reassurance to both clinicians and parents as to the safety of inhaled corticosteroids at conventional low doses in light of recent case reports regarding the adverse effects of high doses of inhaled fluticasone in asthmatic children.⁶ It is worth noting that, currently in the UK, the highest licensed recommended daily dose of budesonide in children is 800 µg/day compared with 200 µg/day for fluticasone propionate.

We have previously found, in asthmatic children, differences between single evening doses of inhaled fluticasone propionate and budesonide of 800 µg or more in terms of adrenal suppression, with fluticasone causing detectable suppression whilst budesonide caused none even with a single dose of 1250 µg.³ These results were in keeping with those of Todd *et al* who also found marked adrenal suppression with high dose (≥1000 µg/day) inhaled fluticasone.⁶ We have also found similar changes in a single evening dosing comparison of fluticasone and budesonide in adult asthmatics⁷ which showed a difference in plasma cortisol levels at 08.00 hours between the drugs at doses above 1000 µg. However, with repeated twice daily dosing in adult asthmatics differences in suppression of 08.00 plasma cortisol levels occurred with doses as low as 250 µg twice daily with a mean treatment difference of 23% for cortisol suppression at 08.00 hours.⁸

Similar results have also been seen in studies on healthy adult volunteers using plasma corti-

Table 1 Overnight urinary cortisol excretion and cortisol/creatinine excretion in asthmatic children given budesonide (BUD) or fluticasone propionate (FP) in doses of 100 µg and 200 µg twice daily

	BUD 100 µg bid	BUD 200 µg bid	FP 100 µg bid	FP 200 µg bid
Overnight urinary cortisol	1.03 (0.46 to 1.61)	1.04 (0.62 to 1.46)	1.11 (0.45 to 1.77)	1.12 (0.78 to 1.47)
Overnight urinary cortisol/creatinine	1.33 (0.43 to 2.23)	0.99 (0.47 to 1.50)	0.99 (0.66 to 1.32)	1.16 (0.72 to 1.59)

Ratios for fold difference between each active treatment versus placebo are shown as means (95% CI). Those 95% CI which include unity indicate no significant difference between active treatment and placebo.

sol AUC₀₋₂₀, revealing an accentuation of the differences between fluticasone and budesonide with repeated dosing compared with single doses.⁹ Boorsma *et al* also found differences between the two drugs in healthy volunteers with a 20% treatment difference in suppression of plasma cortisol AUC₀₋₂₄ at a dose of 200 µg twice daily.¹⁰ These results are explained by the pharmacological properties of these drugs as, with chronic dosing, the longer plasma elimination half life of fluticasone of 14.4 hours¹¹ compared with 2.3 hours for budesonide¹² and the greater lipophilicity of fluticasone¹³ will result in greater plasma and tissue retention. This, in conjunction with increased steroid potency and affinity for fluticasone, would be expected to accentuate the differences found between fluticasone and budesonide from the level of suppression already seen with single dosing.

The absence of detectable adrenal suppression with chronic dosing in children therefore appears initially to be somewhat surprising in view of our previous paediatric single dosing results and the marked step up seen between single and chronic dosing in adults. However, one possible explanation for this is the increased plasma clearance of corticosteroids in children compared with adults which has been demonstrated with budesonide. Pedersen *et al* found that plasma clearance of budesonide was 40% greater in children with a shorter elimination half life of 1.5 hours compared with 2.3 hours in adults.¹⁴ It is conceivable, although we are unaware of any confirmatory data, that the steady state clearance of fluticasone also differs between children and adults. Another major factor is the marked difference in dosage between our paediatric single and repeated dosing designs. The dose of fluticasone which showed a difference in adrenal suppression compared with budesonide as single evening doses of these drugs was 800 µg whereas the highest evening dose in the present chronic dosing study was only 200 µg.

There are few peer reviewed published data on the systemic activity of fluticasone propionate compared with other inhaled corticosteroids in children. Our results are in line with the findings of Wolthers *et al* who studied the effects of chronic dosing with budesonide in doses of 200–800 µg/day via an MDI plus Nebuhaler and found no evidence of a dose response effect on 24 hour urinary free cortisol excretion.¹⁵ Fluticasone has also been assessed with chronic dosing at 100 µg twice daily via an MDI and spacer and no changes were seen in plasma cortisol levels at 08.00–10.00 hours.¹⁶ In an abstracted comparison of fluticasone and budesonide given as dry powder inhalers in doses of 200–400 µg/day no significant effects were found on a battery of bone, growth, and collagen markers.¹⁷ In contrast, beclomethasone dipropionate in doses of 400 µg/day and 800 µg/day caused significantly lower short term growth velocity (knemometry) than fluticasone in a dose of 200 µg/day given by dry powder inhaler.¹⁸

Finally, it is also important to consider the amount of fine particle dose delivered from the device as this will determine the lung bio-

availability and hence systemic activity.¹⁹ In this respect the addition of a Nebuhaler to the MDI for budesonide has been shown to increase the in vitro respirable fraction from 8% to 27% using an Andersen sampler in conjunction with an anatomical child throat.²⁰ Furthermore, in vitro data using identical methodology have shown that the respirable fraction for budesonide Turbuhaler is 30%²¹ so it is likely that the data for budesonide via a Nebuhaler (27% respirable fraction) can be extrapolated to the Turbuhaler.

In conclusion, we have found that twice repeated daily dosing with inhaled budesonide and fluticasone propionate given via a large volume spacer in a dose range of 200–400 µg/day did not cause any detectable adrenal suppression in asthmatic children.

This study was funded by a grant from the Astra Foundation (UK).

- 1 British Thoracic Society. Chronic asthma in adults and children. *Thorax* 1993;48(Suppl):S1–24.
- 2 Barnes PJ. Inhaled glucocorticoids for asthma. *N Engl J Med* 1995;332:868–75.
- 3 Clark DJ, Clark RA, Lipworth BJ. Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. *Thorax* 1996;51:941–3.
- 4 English AF, Neate MS, Quint DJ, Sareen M. Biological activities of some corticosteroids used in asthma (abstract). *Am J Respir Crit Care Med* 1994;149(Suppl):A212.
- 5 Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. *Steroids* 1994;59:597–602.
- 6 Todd G, Dunlop K, McNaboe J, Ryan MF, Carson D, Shields MD. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. *Lancet* 1996;348:27–9.
- 7 Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. *Thorax* 1996;51:262–6.
- 8 Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. *Thorax* 1997;52:55–8.
- 9 Lonnebo A, Grahnen A, Jansson B, Brundin RM, Ling-Andersson A, Eckernas SA. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in normal volunteers. *Eur J Clin Pharmacol* 1996;49:459–63.
- 10 Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. *Eur Respir J* 1996;9:1427–32.
- 11 Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. *Br J Clin Pharmacol* 1997;43:155–61.
- 12 Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from pressurised metered-dose inhaler. *Eur Respir J* 1994;7:1839–44.
- 13 Wurthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. *Pharm Ztg Wiss* 1992;4:161–7.
- 14 Pedersen S, Steffensen G, Ekman I, Tonnesson M, Borga A. Pharmacokinetics of budesonide in children with asthma. *Eur J Clin Pharmacol* 1987;31:579–82.
- 15 Wolthers OD, Pedersen S. Measures of systemic activity of inhaled glucocorticoids in children: a comparison of urine cortisol excretion and knemometry. *Respir Med* 1995;89:347–9.
- 16 Gustafsson P, Tsanakis J, Gold M, Primhak R, Radford M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 µg/day with inhaled beclomethasone dipropionate 400 µg/day in mild and moderate asthma. *Arch Dis Child* 1993;69:206–11.
- 17 Agertoft L, Pedersen S. Bone, growth and collagen markers in children treated with fluticasone propionate and budesonide (abstract). *Eur Respir J* 1996;9(Suppl 23):295s.
- 18 Wolthers O, Pedersen S. Short term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. *Arch Dis Child* 1993;68:673–6.
- 19 Lipworth BJ. Airway and systemic effects of inhaled corticosteroids in asthma: dose-response relationship. *Pulm Pharmacol* 1996;9:19–27.
- 20 Berg E. In vitro properties of pressurised metered dose inhalers with and without spacer devices. *J Aerosol Med* 1995;8(Suppl 3):S3–11.
- 21 Olsson B. Aerosol particle generation from dry powder inhalers: can they equal pressurised metered dose inhalers? *J Aerosol Med* 1995;8(Suppl 3):S13–18.